Hep C Flashcards
How is Hep A transmitted?
Fecal-oral route -person to person and contamination of water
What can you admister as post exposure prophylaxis for a patient infected with Hep A?
Immune globulin (IG) within 2 weeks- stimulates the immune system to recognize the virus
Havrix
MOA- Inactivation Hep A vaccine, inducing the production of specific anti-HAV antibodies
IM Injection
WARNINGS- Latex allergy, bleeding disorder
Monior- LFT, serum neutralizing antibody to Hep A virus (HAVAB and HAVAB-M RIA)
Dosage- adults- 1ml followed by 1ml booster (6-12 months later)
Children- 0.5ml followed by 0.5 ml booster (6-12 months later)
Vaqta
MOA- Inactivation Hep A vaccine, inducing the production of specific anti-HAV antibodies
IM Injection
WARNINGS- Latex allergy, bleeding disorder
Monior- LFT, serum neutralizing antibody to Hep A virus (HAVAB and HAVAB-M RIA)
Dosage- adults- 1ml followed by 1ml booster (6-18 months later)
Children- 0.5ml followed by 0.5 ml booster (6-18 months later)
How old do you need to be to get the Hep A vaccine
at least 12 months for either havrix or Vaqta
How is Hep B tramsmitted?
Blood, Brith and Boinking
unportected sex
mutiple partners
Hep C medication can reactivate Hep B
Which antiviral meications can treat HBV?
Entacavir
Tenofovir
Lamivudine
Adefovir
Telbivudine
Engerix B
3 dose series vaciines for Hep B
MOA- recombinant DNA hepatitis B vaccine whihc contains purified surface antigen for the hepatitis B virus
IM injection
WARNING- syncope, apnea in premature infants, dimished immune response in immunoconpromised patients, latex allergy
Monitor- Hep B surface antibody levels
Adminstration schedule- adults 20 years and older (1ml 0,1,6 months) adults on hemodialysis 2ml (0,1,2,6 months)
Heplisav-B
2 dose series for Hep B
MOA- purified HBV surface antigen (hBsAg) with an adjuvant and is used to increase antibody concentrations against HBsAg inorder to confer protection against all known subtypes of hep b virus infections for patients 18 years and older
IM injection
2 dosees 1 month apart
ADR- cell-mediated immune reaction
Monitor- Hep B surface antibody levels
Recomivax
3 dose series vaciines for Hep B
MOA- recombinant DNA hepatitis B vaccine whihc contains purified surface antigen for the hepatitis B virus
IM injection
WARNING- latex allergy, apnea in premature infants, concomitant administration with immune globulin
Monitor- Hep B surface antibody levels
Adults- 3 dose (0, 1, 6 months)
Twinrix
Hep A and Hep B vaccination
MOA- contians inactivated Hep A virus and purified HBsAg that confers active immunity against infectins caused by Hep A virus and all known Hep B virus suntypes
Adminsitration
- Standard- 3 doses (1ml) IM injection at 0, 1, 6 months
- Accelerated- 4 doeses (1ml) IM injection (days 0, 7, 21-30, follwed by a booster dose at 12 months)
Monitoring- rise in anti- HAV at least 20 mIU/mL and anti-HBa levels at 1 mlIU. ML
How is Hep C transmitted?
Blood- blood transfusions, organ trasnplant, sharing needles
Vertical transmission- mother to baby
Sexual contact
NO VACCINE AVAILABLE
What is the goal of Hep C therapy and who should get it?
Reduce mortality rates and preven progression of any other liver-related health conditions by achieving sustained virologic respsone (SVR)
Recommeded for all patients- initiate treatment in all patients with HCV infections
EXCEPT- patients with a short life expectancy, cannot tolerate HCV therapy, longer 15-20 year survival rate when unntreated
Sofobuvir
NS5B Polymerase Inhibitor
MOA- binds to active site to prevent RNA chain so no replication. Enzyme that incorporated neucloside/ nucleotide analog into RNA chain
Grazoprevir
NS3/4A Protease Inhibitor
MOA- C encodes for capsid and E1/E2 encode for envelop. Protease inhibited so virus cannot cleave proteins (non functional) cleaves non structural polyproteins that are utilized in HCV RNA replication
Glecaprevir
NS3/4A Protease Inhibitor
MOA- C encodes for capsid and E1/E2 encode for envelop. Protease inhibited so virus cannot cleave proteins (non functional) cleaves non structural polyproteins that are utilized in HCV RNA replication
Paritaprevir
NS3/4A Protease Inhibitor
MOA- C encodes for capsid and E1/E2 encode for envelop. Protease inhibited so virus cannot cleave proteins (non functional) cleaves non structural polyproteins that are utilized in HCV RNA replication
Simeprevir
NS3/4A Protease Inhibitor
MOA- C encodes for capsid and E1/E2 encode for envelop. Protease inhibited so virus cannot cleave proteins (non functional) cleaves non structural polyproteins that are utilized in HCV RNA replication
Voxilaprevir
NS3/4A Protease Inhibitor
MOA- C encodes for capsid and E1/E2 encode for envelop. Protease inhibited so virus cannot cleave proteins (non functional) cleaves non structural polyproteins that are utilized in HCV RNA replication
Daclatasvir
NS5A Inhibitor
MOA- stops phosphorylation (decrease energy= decrease cell function) Hep C RNA cannot be replicated. Phosphorylates protein required for replication
Elbasvir
NS5A Inhibitor
MOA- stops phosphorylation (decrease energy= decrease cell function) Hep C RNA cannot be replicated. Phosphorylates protein required for replication
Ledipasvir
NS5A Inhibitor
MOA- stops phosphorylation (decrease energy= decrease cell function) Hep C RNA cannot be replicated. Phosphorylates protein required for replication
Ombitasvir
NS5A Inhibitor
MOA- stops phosphorylation (decrease energy= decrease cell function) Hep C RNA cannot be replicated. Phosphorylates protein required for replication
Pibrentasvir
NS5A Inhibitor
MOA- stops phosphorylation (decrease energy= decrease cell function) Hep C RNA cannot be replicated. Phosphorylates protein required for replication
Velpatasvir
NS5A Inhibitor
MOA- stops phosphorylation (decrease energy= decrease cell function) Hep C RNA cannot be replicated. Phosphorylates protein required for replication
Dasabuvir
Non- Nucleoside NS5B Palm Polymerase Inhibitor
MOA- binds to allosteric site which causes a confirmational change and RNA cannot bind and replicate. Enzyme that incorporates nucleoside/nucleotide aanalog into RNA chain
Ritonavir
3A4 PK Booster
MOA- Increase concentration of other meds. Used in combination with other anti-virals.
Which antivirals work with genotype 1a/1b?
-
Zepatier (Elbasvir/ Grazoprevir)
- without cirrhosis (daily 12 weeks)
- with cirrhosis (daily 12 week)
-
Mavyret (Glecaprevir/ Pibrentasvir)
- without cirrhosis (daily 8 weeks)
- with cirrhosis (daily 12 week)
-
Harvoni (Ledipasvir/ Sofosbuvir)
- without cirrhosis (daily 8 weeks)
- HCV levels <6 million IU/mL
- if greater then daily 12 weeks
- with cirrhosis (daily 12 week)
- without cirrhosis (daily 8 weeks)
-
Epclusa (Velpatasvir/ Sofosbuvir)
- without cirrhosis (daily 12 weeks)
- with cirrhosis (daily 12 week)
Which antiviral work with genotype 2?
-
Mavyret (Glecaprevir/ Pibrentasvir)
- without cirrhosis (daily 8 weeks)
- with cirrhosis (daily 8 week)
-
Epclusa (Velpatasvir/ Sofosbuvir)
- without cirrhosis (daily 12 weeks)
- with cirrhosis (daily 12 week)
Which antiviral work with genotype 3?
-
Mavyret(Glecaprevir/ Pibrentasvir)
- without cirrhosis (daily 8 weeks)
- with cirrhosis (daily 12 week)
-
Epclusa (Velpatasvir/ Sofosbuvir)
- without cirrhosis (daily 12 weeks)
- with cirrhosis (daily 12 week)
Which antiviral work with genotype 4?
-
Zepatier(Elbasvir/ Grazoprevir)
- without cirrhosis (daily 12 weeks)
- with cirrhosis (daily 12 week)
-
Mavyret(Glecaprevir/ Pibrentasvir)
- without cirrhosis (daily 8 weeks)
- with cirrhosis (daily 12 week)
-
Harvoni (Ledipasvir/ Sofosbuvir)without cirrhosis (daily 8 weeks)
- without cirrhosis (daily 12 weeks)
- with cirrhosis (daily 12 week)
-
Epclusa (Velpatasvir/ Sofosbuvir)
- without cirrhosis (daily 12 weeks)
- with cirrhosis (daily 12 week)
Which antivirlas work with genotype 5/6?
-
Mavyret (Glecaprevir/ Pibrentasvir)
- without cirrhosis (daily 8 weeks)
- with cirrhosis (daily 12 week)
-
Harvoni (Ledipasvir/ Sofosbuvir)without cirrhosis (daily 8 weeks)
- without cirrhosis (daily 12 weeks)
- with cirrhosis (daily 12 week)
-
Epclusa (Velpatasvir/ Sofosbuvir)
- without cirrhosis (daily 12 weeks)
- with cirrhosis (daily 12 week)
Sovaldi (Sofosbuvir)- side effects and monitoring
side effects- fatigue/ headache, GI effects, pruritus, decrease appetite
Monitoring- Pregnancy caution (sofosbuvir alone- category B), Serious DDI, no dosage recommendation for eGFR <30ml
Harvoni (Ledipasvir/ Sofosbuvir) - side effects and monitoring
side effects- Asthenia, Hyperbilirubinemia, fatigue/ headache, GI effects
Monitoring- No hepatic dose adjustment, no renal dose adjustments (caution CrCl <30mL)
Viekira Pak (Paritaprevir/ Ritonavir/ Ombitasvir/ Dasabuvir)- side effects and monitoring
side effects- GI effects, Rash, Elevated LFT
Monitoring- No renal/ hepatic dose adjustment, major DDI, C/I in patients with moderate or severe hepatic impairment, drugs that are CYP3A4 inhibitors/ inducers
Daklinza (Daclatasvir/ Sofosbuvir)- side effects and monitoring
side effects- Anemia, fatigue/ headache, GI effects
Monitoring- C/I with CYP Inducers, dose adjustments based on CYP3A4 sunstrates
Technivie (Ombitasvir/ Paritaprevir/ Ritonavir)- side effects and monitoring
side effects- Asthenia, Fatigue/ Headache, GI effects, Pruritis/ skin reactions
Monitoring- No renal dose adjustment, C/I patient with hepatic moderate to severe impairment,
Zepatier (Elbasvir/ Grazoprevir)- side effects and monitoring
side effects- Anemia, Elevated LFT, Fatigue/ Headache, GI effects
Monitoring- No hepatic/ renal dose adjustment, C/I patient with moderate or severe hepatic impairment
Epclusa (Sofosbuvir/ Velpatasvir) - side effects and monitoring
side effects- Anemia, GI effects, fatigue/ headache
Monitoring- No hepatic/ renal dose adjustment, Major DDI
Vosevi (Sofosbuvir/ Velpatasvir/ Voxilaprevir)- side effects and monitoring
side effects- Fatigue/ headache, GI effects, Rash, Depression, Elevated lipase, CPK, T.bili
Monitoring- Majot DDI, do not use if eGFR < 30ml
Mavyret (Glecaprevir/ Pibrentasvir)- side effects and monitoring
side effects- fatigue, GI effects, Elevated t.bili
Monitoring- No renal dose adjustment, C/I patient with hepatic impairment, atazanavir or rifampin
Interferon
Peginterferon alfa-2a
Peginterferon alfa-2b
MOA- induces innate antiviral immune respnse
Side effects- injection site reaction, flu-like aymptoms, alopecia, thrombocytopenia, leukopenia, photosensitivity
BBB warning- fatal neuropsychiatric, autoimmune, ischemic and infectious disorders (CNS psychosis & arrhythmia)
Ribavirin
MOA- inhibits HCV viral polymerase activity
ADR- Anemia, injection site reaction, weight loss, diarrhea, insomnia, weakness, flu-like symptoms, hepatotoxicity (in combo with interferon)
BBB Warning- Hemolytic Anemia, Teratogenic
Hep C medication monitoring
Prior to therapy
- CBC, INR, LFT, eGRF
During therapy
- HCV viral load (week 4 and end of therapy)
- routine labs
- monitor DDI
After therapy
- Check HCV viral load 12 weeks after end of therapy
- must be undetectable for SVR
DDI with Amiodarone and Digoxin
- Which HCV agents
- Interactions
- Recommendations
HCV Agents- Harvoni, Epclusa, Zepatier, Mavyret
Interactions- Symptomatic bradycardia
Recommendation- reduce digoxin by 50%, monitor EKG during therpy
DDI with Antacids (H2 antagonist, PPI)
- Which HCV agents
- Interactions
- Recommendations
Which HCV agents- Epclusa, Vosevi, Harvoni
Interactions- decreasde antiviral concentration
Recommendations- seperate by 4 hours or select different HCV agent
DDI with Phenytoin
- Which HCV agents
- Interactions
- Recommendations
Which HCV agents- Harvoni, Epclusa, Zepatier, Mavyret
Interactions- Decreased antiviral concentration (P-gp activation and CYP inhibition)
Recommendations- contraindicated use another anti-epileptic (Keppra, Lamictal, Depakote)
DDI with Rifampin
- Which HCV agents
- Interactions
- Recommendations
Which HCV agents- Harvoni, Epclusa, Zepatier, Mavyret
Interactions- Decreased antiviral concentration (P-gp activation and CYP inhibition)
Recommendations- contraindicated
How to diagnose Hep C?
LFT, imagining, liver biopsy
First serologic test of antibody to HCV (anti-HCV)
- non reactive= no Hep C
- Reactive= further Hep C testing
Further Hep C testing
- Molecular assay for HCV RNA- tests for viral load